Bianca Orlando

Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study

Piero Barbanti, Cinzia Aurilia, Gabriella Egeo et al. · Journal of Neurology · 2024 · 34 citations · Full text

Life Sciences, Neurology, Pharmacology +17

Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study

Piero Barbanti, Cinzia Aurilia, Paola Torelli et al. · Journal of Neurology · 2025 · 22 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years

Tommaso Guerra, Francesca Caputo, Bianca Orlando et al. · Neurological Sciences · 2021 · 17 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +14

Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Piero Barbanti, Gabriella Egeo, Stefania Proietti et al. · Neurology and Therapy · 2024 · 17 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study

Piero Barbanti, Cinzia Aurilia, Gabriella Egeo et al. · Journal of Neurology · 2024 · 14 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17